Stock Track | Aurinia Pharmaceuticals Soars 9.23% Pre-Market on Jefferies Upgrade and Doubled Price Target

Stock Track11-07

Shares of Aurinia Pharmaceuticals (AUPH) are soaring 9.23% in pre-market trading on Friday, following a significant upgrade from Jefferies. The investment bank raised its rating on the biopharmaceutical company from Hold to Buy, while more than doubling its price target from $10 to $21.

The upgrade comes as Jefferies expresses increased confidence in Aurinia's commercial performance. This positive outlook suggests that the company's key product, LUPKYNIS, approved for the treatment of lupus nephritis, may be gaining traction in the market. The substantial increase in the price target implies that Jefferies sees considerable upside potential for Aurinia's stock.

This bullish stance from Jefferies aligns with the overall positive sentiment among analysts covering Aurinia Pharmaceuticals. According to FactSet, the company currently has an average rating of Buy, with a mean price target of $16.29. The latest upgrade and increased price target from Jefferies could potentially lead other analysts to reassess their positions on the stock, potentially driving further investor interest in Aurinia Pharmaceuticals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141642479?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141642479","market":"sg","top_or_hot":-1,"title":"Stock Track | Aurinia Pharmaceuticals Soars 9.23% Pre-Market on Jefferies Upgrade and Doubled Price Target","media":"Stock Track","content":"<p>Shares of Aurinia Pharmaceuticals (AUPH) are soaring 9.23% in pre-market trading on Friday, following a significant upgrade from Jefferies. The investment bank raised its rating on the biopharmaceutical company from Hold to Buy, while more than doubling its price target from $10 to $21.</p>\n\n<p>The upgrade comes as Jefferies expresses increased confidence in Aurinia's commercial performance. This positive outlook suggests that the company's key product, LUPKYNIS, approved for the treatment of lupus nephritis, may be gaining traction in the market. The substantial increase in the price target implies that Jefferies sees considerable upside potential for Aurinia's stock.</p>\n\n<p>This bullish stance from Jefferies aligns with the overall positive sentiment among analysts covering Aurinia Pharmaceuticals. According to FactSet, the company currently has an average rating of Buy, with a mean price target of $16.29. The latest upgrade and increased price target from Jefferies could potentially lead other analysts to reassess their positions on the stock, potentially driving further investor interest in Aurinia Pharmaceuticals.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Aurinia Pharmaceuticals Soars 9.23% Pre-Market on Jefferies Upgrade and Doubled Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Aurinia Pharmaceuticals Soars 9.23% Pre-Market on Jefferies Upgrade and Doubled Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Aurinia Pharmaceuticals (AUPH) are soaring 9.23% in pre-market trading on Friday, following a significant upgrade from Jefferies. The investment bank raised its rating on the biopharmaceutical company from Hold to Buy, while more than doubling its price target from $10 to $21.</p>\n\n<p>The upgrade comes as Jefferies expresses increased confidence in Aurinia's commercial performance. This positive outlook suggests that the company's key product, LUPKYNIS, approved for the treatment of lupus nephritis, may be gaining traction in the market. The substantial increase in the price target implies that Jefferies sees considerable upside potential for Aurinia's stock.</p>\n\n<p>This bullish stance from Jefferies aligns with the overall positive sentiment among analysts covering Aurinia Pharmaceuticals. According to FactSet, the company currently has an average rating of Buy, with a mean price target of $16.29. The latest upgrade and increased price target from Jefferies could potentially lead other analysts to reassess their positions on the stock, potentially driving further investor interest in Aurinia Pharmaceuticals.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUPH","symbol_name":"Aurinia Pharmaceuticals Inc","start_time":0,"source_url":"","article_id":"1141642479","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141642479","pubTimestamp":1762527020,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Aurinia Pharmaceuticals (AUPH) are soaring 9.23% in pre-market trading on Friday, following a significant upgrade from Jefferies. The investment bank raised its rating on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc"},"translate_title":"个股追踪|Aurinia Pharmaceuticals盘前大涨9.23%，目标价翻倍","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":1},"content_text":"Shares of Aurinia Pharmaceuticals (AUPH) are soaring 9.23% in pre-market trading on Friday, following a significant upgrade from Jefferies. The investment bank raised its rating on the biopharmaceutical company from Hold to Buy, while more than doubling its price target from $10 to $21.\nThe upgrade comes as Jefferies expresses increased confidence in Aurinia's commercial performance. This positive outlook suggests that the company's key product, LUPKYNIS, approved for the treatment of lupus nephritis, may be gaining traction in the market. The substantial increase in the price target implies that Jefferies sees considerable upside potential for Aurinia's stock.\nThis bullish stance from Jefferies aligns with the overall positive sentiment among analysts covering Aurinia Pharmaceuticals. According to FactSet, the company currently has an average rating of Buy, with a mean price target of $16.29. The latest upgrade and increased price target from Jefferies could potentially lead other analysts to reassess their positions on the stock, potentially driving further investor interest in Aurinia Pharmaceuticals.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141642479","isCrawlerRequest":true}